TrialBritish journal of cancer2022

Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.

Dana M Roque et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.